MP16-11 RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY IS ONCOLOGICALLY SAFE MODE OF SURGICAL TREATMENT OF PROSTATE CANCER: ANALYSIS OF 359 CASES

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy III1 Apr 2018MP16-11 RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY IS ONCOLOGICALLY SAFE MODE OF SURGICAL TREATMENT OF PROSTATE CANCER: ANALYSIS OF 359 CASES Ali Raheem, Ki Don Chang, Mohammed Alenzi, Ahmed Elghiaty, Tariq Alomir, Jong Won Kim, Won Sik Ham, Woong Kyu Han, Young Deuk Choi, and Koon Ho Rha Ali RaheemAli Raheem More articles by this author , Ki Don ChangKi Don Chang More articles by this author , Mohammed AlenziMohammed Alenzi More articles by this author , Ahmed ElghiatyAhmed Elghiaty More articles by this author , Tariq AlomirTariq Alomir More articles by this author , Jong Won KimJong Won Kim More articles by this author , Won Sik HamWon Sik Ham More articles by this author , Woong Kyu HanWoong Kyu Han More articles by this author , Young Deuk ChoiYoung Deuk Choi More articles by this author , and Koon Ho RhaKoon Ho Rha More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.545AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Data regarding the oncologic outcomes of Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) is lacking. Our aim was to evaluate the predictors of biochemical recurrence (BCR) following RS-RARP. METHODS The study cohort consisted of 359 consecutive non-metastatic PCa patients who underwent RS-RARP between November 2012 and January 2016. According to NCCN PCa risk classification 164 patients (45.7%) had high-risk prostate cancer (PCa). No patient received adjuvant therapy until documented BCR. BCR free-survival (BCRFS) was estimated using the Kaplan-Meier method. Univariable and multivariable Cox proportional hazards regression models were used to determine variables predictive of BCR. RESULTS The median follow-up was 26 months (IQR: 19-38). The overall BCR rate was 53 (14.8%), and the median time to BCR was 11 months (IQR: 6-22). The 3-year BCRFS probability was 88.7%, 82.3%, and 95.7% in high-, intermediate-, low-risk PCa, respectively (log-rank, p<0.001). On multivariable analysis, preoperative PSA (HR: 1.03; 95%CI, 1.02–1.04; p<0.0001), percentage of maximum core involvement on biopsy (HR: 1.02; 95%CI, 1.01–1.03; p=0.029), and c-T-stage =T3a (HR: 2.12; 95%CI, 1.02-4.39; p=0.043) were predictors of BCR, while pathologic Gleason score =8 (HR: 5.63; 95%CI, 1.62–19.61; p=0.007) and pathologic tumor volume (HR: 1.08; 95%CI, 1.04–1.20; p<0.001) were the main pathological predictors of BCR. CONCLUSIONS In a contemporary cohort of patients with a large number of high-risk PCa, RS-RARP is safe and confers effective 3-year BCR control similar to large reports of conventional robotic prostatectomy. Longer follow-up is needed to further evaluate its long-term oncologic safety. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e201 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ali Raheem More articles by this author Ki Don Chang More articles by this author Mohammed Alenzi More articles by this author Ahmed Elghiaty More articles by this author Tariq Alomir More articles by this author Jong Won Kim More articles by this author Won Sik Ham More articles by this author Woong Kyu Han More articles by this author Young Deuk Choi More articles by this author Koon Ho Rha More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...